GILD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GILD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. Gilead Sciences's Goodwill for the quarter that ended in Mar. 2024 was $8,314 Mil. Gilead Sciences's Total Assets for the quarter that ended in Mar. 2024 was $56,292 Mil. Therefore, Gilead Sciences's Goodwill to Asset Ratio for the quarter that ended in Mar. 2024 was 0.15.
The historical data trend for Gilead Sciences's Goodwill-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gilead Sciences Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Goodwill-to-Asset | Get a 7-Day Free Trial | 0.07 | 0.12 | 0.12 | 0.13 | 0.13 |
Gilead Sciences Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Goodwill-to-Asset | Get a 7-Day Free Trial | 0.13 | 0.13 | 0.13 | 0.13 | 0.15 |
For the Drug Manufacturers - General subindustry, Gilead Sciences's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Goodwill-to-Asset distribution charts can be found below:
* The bar in red indicates where Gilead Sciences's Goodwill-to-Asset falls into.
Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.
It is calculated by dividing goodwill by total assets.
Gilead Sciences's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Goodwill to Asset (A: Dec. 2023 ) | = | Goodwill | / | Total Assets |
= | 8314 | / | 62125 | |
= | 0.13 |
Gilead Sciences's Goodwill to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as
Goodwill to Asset (Q: Mar. 2024 ) | = | Goodwill | / | Total Assets |
= | 8314 | / | 56292 | |
= | 0.15 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gilead Sciences (NAS:GILD) Goodwill-to-Asset Explanation
If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.
Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.
Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.
Thank you for viewing the detailed overview of Gilead Sciences's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Andrew D Dickinson | officer: EVP, Chief Financial Officer | 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Johanna Mercier | officer: Chief Commercial Officer | 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Merdad Parsey | officer: Chief Medical Officer | 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Sandra Patterson | officer: SVP, Controllership | 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Diane E. Wilfong | officer: SVP, Controller & CAO | 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Deborah H Telman | officer: EVP, Corporate Affairs & GC | 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
Brett A Pletcher | officer: EVP, Gen Counsel & Corp Sec | 333 LAKESIDE DRIVE, FOSTER CITY X1 94404 |
Jeffrey Bluestone | director | C/O PROVENTION BIO, INC., P.O. BOX 666, OLDWICK NJ 08858 |
Anthony Welters | director | |
Javier Rodriguez | director | 601 HAWAII ST., EL SEGUNDO CA 90245 |
John Francis Cogan | director | 2010 NORTH FIRST STREET, SUITE 310, SAN JOSE CA 95131 |
Gayle E Wilson | director | C/O GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Olsen Per Wold | director | C/O GILEAD SCIENCES, 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Sandra Horning | director | 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Richard James Whitley | director | UAB, CHB 303, 1600 7TH AVENUE SOUTH, BIRMINGHAM AL 35233-1711 |
From GuruFocus
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.